The clinical characteristics and prognosis of de novo acute myeloid leukemia patients with CCAAT/enhancer binding protein α mutations

Abstract

Objective To explore the clinical characteristics and prognosis of acute myeloid leukemia(AML)patients with CCAAT/enhancer binding protein α(CEBPA)mutations. Methods 208 patients with de novo AML were retrospectively analyzed with regard to frequency of CEBPA mutations, clinical characteristics, therapeutic response and long-term outcome. Results CEBPA mutations were detected in 37 patients(17.8 %), with 29 cases of double mutations and 8 cases of single mutation. In 117 cases of patients with normal karyotype, 28 cases(23.9 %)were detected with CEBPA mutations. As compared with no CEBPA mutation, the following characteristics were observed in patients with CEBPA double mutations. Presented with younger age at diagnosis, 82.8 %(24/29)of the patients were M1 and M2. Presented with higher peripheral white blood cell count, higher hemoglob in and low platelet count. And increases of CD7, CD34 and HLA-DR expression. Compared with those without mutation, patients with biCEBPA mutations had better overall survival(OS)(2-years OS: 100 % vs 75.1 %, P = 0.045). Conclusion BiCEBPA mutation is one of the favorable prognosis indicators. Key words: Leukemia, myeloid, acute; CCAAT/enhancer binding protein α mutations; Immunophenotype; Prognoses